As our focus expands from approvals to outcomes, fluency with real-world data, and the tools to generate and analyze this information, will be ever-more critical. Amy Abernethy has the right experience, attributes, and instincts to catalyze the FDA’s embrace of this imminent patient-centric future.
Amy Abernethy: Poised To Propel FDA Into Tech-Savvy, Patient-Centric Future
